Solara Active Pharma Sciences Limited — financial distress indicators
Financial-health summary
Solara Active Pharma Sciences Limited's reported numbers place it in the 'Watch' financial-health band (distress score 47/100). The main indicators are operating profit does not cover interest, ohlson o-score signals likely failure and current liabilities exceed current assets. Independently, the Ohlson accounting model puts its 1-year failure probability at 57% and the market-implied (Merton) default probability is 0.0%. In its favour: operating cash flow is positive over the latest 12 months.
Stress by dimension
Share price — last 12 months
Indicators behind the score
Each red flag shows the evidence from the company’s own filings and the financial or legal principle behind it. Points add to the 0–100 score.
Interest coverage (EBIT / interest) is 0.96×.
When EBIT < interest, debt service is funded from cash reserves or new borrowing — the classic precursor to payment default and covenant breach.
O-score 0.29 → model probability 57%.
Ohlson (1980) logit model of 1-year corporate failure; O > 0 (p > 50%) is the original failure cut-off.
Current ratio is 0.96.
Short-term obligations exceed short-term resources — the company relies on rolling over credit.
Recurring net losses.
Repeated losses are a core input in both Ohlson and Altman failure models.
Short-term debt is 10.8× cash on hand.
Maturity wall: debt due within a year must be refinanced, which is the most common proximate cause of filings.
Revenue vs net income
Cash generation
Debt vs cash vs equity
✅ Mitigating factors
- Operating cash flow is positive over the latest 12 months.
- High insider/promoter ownership (52%) aligns management with survival.
📰 Recent news scan
- Solara Active Pharma Sciences Ltd (BOM:541540) Q1 2027 Earnings Call Highlights: Strong Revenue ...Yahoo Finance · 2026-07-25
- Solara Active Pharma Sciences Ltd (BOM:541540) Q4 2026 Earnings Call Highlights: Record Revenue ...Yahoo Finance · 2026-05-15
⚖️ Indian legal pathway — the IBC, 2016
How insolvency starts
- A financial creditor (§7), an operational creditor after a demand notice (§§8–9) or the company itself (§10) can apply to the NCLT once a default of at least ₹1 crore occurs (§4).
- On admission a moratorium (§14) stops suits and recovery; the board is suspended and an insolvency professional runs the company.
- The Committee of Creditors approves a resolution plan with 66% of voting share (§30(4)) within an outer limit of 330 days (§12); otherwise liquidation (§33) under the §53 waterfall — equity ranks last. Defaulting promoters are generally barred from bidding (§29A).
Earlier warning stages
- RBI's Prudential Framework for Resolution of Stressed Assets (7 June 2019): lenders must review a borrower within 30 days of default and implement a resolution plan, or provide more.
- Listed companies must disclose loan defaults to exchanges under SEBI (LODR); a rating downgrade to “D” is a public signal.
- Auditors must report going-concern uncertainty (SA 570 / Ind AS 1).
Frequently asked questions
What do Solara Active Pharma Sciences Limited's financial-health indicators show?
As of 2026-10-09, Solara Active Pharma Sciences Limited's public financial data places it in the 'Watch' band with a distress score of 47/100, driven by operating profit does not cover interest, ohlson o-score signals likely failure and current liabilities exceed current assets. This is a statistical screen of reported numbers — it does not mean the company is insolvent, has defaulted or will enter insolvency proceedings.
What is Solara Active Pharma Sciences Limited's financial distress score?
47/100 ('Watch'). Ohlson O-score 0.29 (model 1-year failure probability 57%). Merton distance-to-default 4.21 σ (model default probability 0.0%).
What works in Solara Active Pharma Sciences Limited's favour?
Operating cash flow is positive over the latest 12 months. High insider/promoter ownership (52%) aligns management with survival.
How are shareholders treated if a company enters insolvency?
Under the IBC the Committee of Creditors controls the resolution; the §53 waterfall pays secured creditors and workers first and equity last. In most resolution plans existing shareholders are wiped out or left with a token stake, and the company may be delisted.
Other Pharma & Biotech companies with distress indicators
- Krebs Biochemicals & Industries Limited (KREBSBIO)Very weak 100/100
- Vivimed Labs Limited (VIVIMEDLAB)Very weak 100/100
- Mangalam Drugs & Organics Limited (MANGALAM)Very weak 90/100
- Lasa Supergenerics Limited (LASA)Very weak 82/100
- Ortin Global Limited (ORTINGLOBE)Very weak 77/100
- Zota Health Care Limited (ZOTA)Very weak 72/100
Methodology
Score = capped sum of rule-based red flags across seven dimensions (liquidity, solvency, profitability, cash flow, sales trend, market signal, news). Ohlson O-score (1980) gives an accounting-based 1-year failure probability; Merton distance-to-default (Bharath & Shumway 2008) gives a market-implied probability. Financial institutions use a capital-based rule set. Recalculated every trading day from the latest filings, prices and news.